心臟彩色多普勒超聲評價壓力負(fù)荷超載誘導(dǎo)的舒張性心力衰竭及益氣溫陽中藥的干預(yù)作用
發(fā)布時間：2018-07-22 11:32
【摘要】：目的:通過心臟彩色多普勒超聲評價壓力負(fù)荷超載誘導(dǎo)的舒張性心力衰竭及益氣溫陽中藥的干預(yù)作用。方法:清潔級雄性Wistar大鼠40只,隨機選取10只為假手術(shù)組,余30只腹主動脈縮窄術(shù)后,隨機分為模型組、中藥組、纈沙坦組,每組10只。造模后8周開始藥物干預(yù),共干預(yù)16周。觀察藥物干預(yù)對心臟彩色多普勒超聲的影響。結(jié)果:1.心肌形態(tài)測量學(xué):造模24周后,模型組大鼠CMI、LVMI明顯增加(P0.05),中藥組的CMI、LVMI和模型組相比差異無統(tǒng)計學(xué)意義(P0.05),纈沙坦組CMI、LVMI和模型組相比差異有統(tǒng)計學(xué)意義(P0.05),中藥組CMI、LVMI與西藥組相比差異無統(tǒng)計學(xué)意義(P0.05)。2.M型超聲心動圖:(1)造模24周后,模型組大鼠IVSd顯著增高(P0.05),中藥組IVSd與模型組相比有減小趨勢,差異無統(tǒng)計學(xué)意義(P=0.069),纈沙坦組IVSd與模型組相比明顯減小(P0.05),中藥組IVSd與纈沙坦組相比差異無統(tǒng)計學(xué)意義(P0.05)。(2)造模24周后,模型組大鼠LV Mass增大(P0.05),中藥組LV Mass與模型組相比有統(tǒng)計學(xué)差異(P0.05),纈沙坦組LV Mass與模型組相比差異有統(tǒng)計學(xué)意義(P0.05),中藥組LV Mass與纈沙坦組相比差異無統(tǒng)計學(xué)意義(P=NS)。(3)造模24周后,模型組大鼠LVIDd明顯增大(P0.05),中藥組LVIDd較模型組減小(P0.05),纈沙坦組LVIDd和模型組比較差異沒有統(tǒng)計學(xué)意義(P0.05),中藥組LVIDd與纈沙坦組相比差異無統(tǒng)計學(xué)意義(P0.05)。(4)造模24周后,模型組大鼠EF、FS降低,但差異無統(tǒng)計學(xué)意義(P0.05),中藥組、纈沙坦組和模型組相比差異無統(tǒng)計學(xué)意義(P0.05,P0.05),中藥組和纈沙坦組相比差異無統(tǒng)計學(xué)意義(P0.05)。3.心臟彩色血流多普勒超聲:(1)造模24周后,模型組E峰顯著減小(P0.05);中藥組E峰較模型組增大(P0.05);纈沙坦組和模型組比較差異無統(tǒng)計學(xué)意義(P0.05),中藥組與纈沙坦組相比差異無統(tǒng)計學(xué)意義(P0.05)。(2)模型組E/A比值顯著降低(P0.05),中藥組E/A比值較模型組顯著提高(P0.05),纈沙坦組E/A比值和模型組相比差異無統(tǒng)計學(xué)意義(P0.05),中藥組E/A比值與纈沙坦組相比差異無統(tǒng)計學(xué)意義(P0.05)。4.血流動力學(xué):(1)造模24周后,模型組SAP明顯升高(P0.05),中藥組SAP較模型組降低(P0.05),纈沙坦組SAP較模型組降低(P0.05),中藥組SAP與纈沙坦組相比差異無統(tǒng)計學(xué)意義(P0.05)。(2)造模24周后,模型組LVSP明顯升高(P0.05),中藥組LVSP較模型組降低(P0.05),纈沙坦組LVSP較模型組降低(P0.05),中藥組LVSP與纈沙坦組相比差異無統(tǒng)計學(xué)意義(P0.05)。(3)造模24周后,模型組LVEDP明顯升高(P0.05),中藥組LVEDP較模型組降低(P0.05),纈沙坦組LVEDP較模型組降低(P0.05),中藥組LVEDP與纈沙坦組相比差異無統(tǒng)計學(xué)意義(P0.05)。結(jié)論:心臟彩色多普勒超聲是評價壓力負(fù)荷超載誘導(dǎo)的舒張性心力衰竭的有效方法,益氣溫陽中藥可有效改善壓力負(fù)荷超載誘導(dǎo)的舒張性心力衰竭。
[Abstract]:Objective: To evaluate the intervention effect of pressure overload induced diastolic heart failure and Yiqi Wenyang traditional Chinese medicine by color Doppler echocardiography. Methods: 40 clean male Wistar rats were randomly selected and 10 were randomly selected as sham operation group and the remaining 30 abdominal aorta coarctation were randomly divided into model group, Chinese medicine group and valsartan group, 10 rats in each group. The drug intervention began 8 weeks after 8 weeks. The effect of drug intervention on color Doppler echocardiography was observed. Results: 1. myocardial morphometry: after 24 weeks of modeling, the model group rats were significantly increased (P0.05), CMI, LVMI and model groups were not statistically significant (P0.05), and the Valsartan group CMI, LVMI and model groups compared with the model group (P0.05). The difference was statistically significant (P0.05). There was no significant difference between CMI and LVMI in Chinese medicine group (P0.05).2.M type echocardiography: (1) after 24 weeks of modeling, IVSd significantly increased in model group (P0.05), and there was no significant difference between the traditional Chinese medicine group IVSd and model group (P=0.069), and the Valsartan group IVSd was more obvious than the model group. There was no significant difference in the difference between IVSd and valsartan group (P0.05). (2) after 24 weeks of modeling, the LV Mass in the model group increased (P0.05). The LV Mass in the Chinese medicine group was significantly different from the model group (P0.05), and the LV Mass in the Valsartan group had a significant difference compared with the model group (P0.05), the Chinese medicine group and the Valsartan group There was no significant difference (P=NS). (3) after 24 weeks of modeling, the model group LVIDd significantly increased (P0.05), the traditional Chinese medicine group LVIDd was less than the model group (P0.05), and there was no statistical difference between the Valsartan group LVIDd and the model group (P0.05), and there was no statistical difference between the traditional Chinese medicine group LVIDd and valsartan group (P0.05). (4) the model group was larger than the model group after 24 weeks. EF, FS decreased, but the difference was not statistically significant (P0.05). There was no significant difference between the traditional Chinese medicine group and the Valsartan group (P0.05, P0.05). There was no significant difference between the Chinese medicine group and the Valsartan group (P0.05).3. heart color Doppler ultrasound: (1) the model group E peak decreased significantly (P0.05) after 24 weeks of modeling, and the E peak of the Chinese medicine group was compared with the model. There was no significant difference between the Valsartan group and the model group (P0.05). There was no significant difference between the Valsartan group and the Valsartan group (P0.05). (2) the E/A ratio in the model group was significantly decreased (P0.05), and the E/A ratio in the Chinese medicine group was significantly higher than that in the model group (P0.05), and there was no statistical difference between the Valsartan group and the model group (P0.). 05) there was no significant difference between the E/A ratio of the Chinese medicine group and the Valsartan group (P0.05).4. hemodynamics: (1) after 24 weeks, the SAP of the model group was significantly higher (P0.05), the SAP in the Chinese medicine group was lower than the model group (P0.05), and the SAP of the Valsartan group was lower than the model group (P0.05). There was no significant difference between the Valsartan group and the Valsartan group (P0.05). (2) the model 24 was 24. After week, the LVSP in the model group increased significantly (P0.05), the LVSP of the Chinese medicine group was lower than the model group (P0.05), and the LVSP in the Valsartan group was lower than the model group (P0.05). There was no significant difference between the Valsartan group and the Valsartan group (P0.05). (3) after 24 weeks of modeling, the model group LVEDP obviously increased (P0.05), the LVEDP of the Chinese medicine group was lower than the model group (P0.05), and the Valsartan group was more than the model group. The model group decreased (P0.05). There was no significant difference between the LVEDP and the Valsartan group (P0.05). Conclusion: color Doppler echocardiography is an effective method to evaluate the diastolic heart failure induced by overload of pressure load. The Yiqi Wenyang Chinese medicine can effectively improve the diastolic heart failure induced by overload of pressure load.
【作者單位】： 上海中醫(yī)藥大學(xué)附屬曙光醫(yī)院;上海中醫(yī)藥大學(xué)附屬第七人民醫(yī)院;上海中醫(yī)藥大學(xué)附屬上海市中醫(yī)醫(yī)院;
【基金】：國家自然科學(xué)基金項目(81102671) 上海市高級中西醫(yī)結(jié)合人才培養(yǎng)項目(ZYSNXD012-RC-ZXY002)
【分類號】：R259
本文編號：2137304
[Abstract]:Objective: To evaluate the intervention effect of pressure overload induced diastolic heart failure and Yiqi Wenyang traditional Chinese medicine by color Doppler echocardiography. Methods: 40 clean male Wistar rats were randomly selected and 10 were randomly selected as sham operation group and the remaining 30 abdominal aorta coarctation were randomly divided into model group, Chinese medicine group and valsartan group, 10 rats in each group. The drug intervention began 8 weeks after 8 weeks. The effect of drug intervention on color Doppler echocardiography was observed. Results: 1. myocardial morphometry: after 24 weeks of modeling, the model group rats were significantly increased (P0.05), CMI, LVMI and model groups were not statistically significant (P0.05), and the Valsartan group CMI, LVMI and model groups compared with the model group (P0.05). The difference was statistically significant (P0.05). There was no significant difference between CMI and LVMI in Chinese medicine group (P0.05).2.M type echocardiography: (1) after 24 weeks of modeling, IVSd significantly increased in model group (P0.05), and there was no significant difference between the traditional Chinese medicine group IVSd and model group (P=0.069), and the Valsartan group IVSd was more obvious than the model group. There was no significant difference in the difference between IVSd and valsartan group (P0.05). (2) after 24 weeks of modeling, the LV Mass in the model group increased (P0.05). The LV Mass in the Chinese medicine group was significantly different from the model group (P0.05), and the LV Mass in the Valsartan group had a significant difference compared with the model group (P0.05), the Chinese medicine group and the Valsartan group There was no significant difference (P=NS). (3) after 24 weeks of modeling, the model group LVIDd significantly increased (P0.05), the traditional Chinese medicine group LVIDd was less than the model group (P0.05), and there was no statistical difference between the Valsartan group LVIDd and the model group (P0.05), and there was no statistical difference between the traditional Chinese medicine group LVIDd and valsartan group (P0.05). (4) the model group was larger than the model group after 24 weeks. EF, FS decreased, but the difference was not statistically significant (P0.05). There was no significant difference between the traditional Chinese medicine group and the Valsartan group (P0.05, P0.05). There was no significant difference between the Chinese medicine group and the Valsartan group (P0.05).3. heart color Doppler ultrasound: (1) the model group E peak decreased significantly (P0.05) after 24 weeks of modeling, and the E peak of the Chinese medicine group was compared with the model. There was no significant difference between the Valsartan group and the model group (P0.05). There was no significant difference between the Valsartan group and the Valsartan group (P0.05). (2) the E/A ratio in the model group was significantly decreased (P0.05), and the E/A ratio in the Chinese medicine group was significantly higher than that in the model group (P0.05), and there was no statistical difference between the Valsartan group and the model group (P0.). 05) there was no significant difference between the E/A ratio of the Chinese medicine group and the Valsartan group (P0.05).4. hemodynamics: (1) after 24 weeks, the SAP of the model group was significantly higher (P0.05), the SAP in the Chinese medicine group was lower than the model group (P0.05), and the SAP of the Valsartan group was lower than the model group (P0.05). There was no significant difference between the Valsartan group and the Valsartan group (P0.05). (2) the model 24 was 24. After week, the LVSP in the model group increased significantly (P0.05), the LVSP of the Chinese medicine group was lower than the model group (P0.05), and the LVSP in the Valsartan group was lower than the model group (P0.05). There was no significant difference between the Valsartan group and the Valsartan group (P0.05). (3) after 24 weeks of modeling, the model group LVEDP obviously increased (P0.05), the LVEDP of the Chinese medicine group was lower than the model group (P0.05), and the Valsartan group was more than the model group. The model group decreased (P0.05). There was no significant difference between the LVEDP and the Valsartan group (P0.05). Conclusion: color Doppler echocardiography is an effective method to evaluate the diastolic heart failure induced by overload of pressure load. The Yiqi Wenyang Chinese medicine can effectively improve the diastolic heart failure induced by overload of pressure load.
【作者單位】： 上海中醫(yī)藥大學(xué)附屬曙光醫(yī)院;上海中醫(yī)藥大學(xué)附屬第七人民醫(yī)院;上海中醫(yī)藥大學(xué)附屬上海市中醫(yī)醫(yī)院;
【基金】：國家自然科學(xué)基金項目(81102671) 上海市高級中西醫(yī)結(jié)合人才培養(yǎng)項目(ZYSNXD012-RC-ZXY002)
【分類號】：R259
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 徐淑樂;楊靖義;周媛;;舒張性心力衰竭中醫(yī)證侯研究進(jìn)展[J];中國實用醫(yī)藥;2014年19期
2 黃雪云;李七一;嚴(yán)士海;;舒張性心力衰竭的中醫(yī)藥治療研究進(jìn)展[J];北京中醫(yī)藥;2014年04期
3 沈曉旭;馬蘇林;王君;李俊平;王顯;王碩仁;;舒張性心力衰竭與中醫(yī)證候分型相關(guān)性研究[J];中國中醫(yī)藥信息雜志;2014年09期
4 李鶴;劉亞洋;汪再舫;;汪再舫運用宗氣理論治療舒張性心力衰竭經(jīng)驗[J];四川中醫(yī);2014年09期
5 黃孟龍;鄭峰;;中醫(yī)對舒張性心力衰竭的認(rèn)識[J];光明中醫(yī);2013年03期
6 孫江順;;80例溫陽化水湯治療舒張性心力衰竭的臨床療效觀察[J];大家健康(學(xué)術(shù)版);2014年11期
7 劉寧;;中藥益心顆粒治療高血壓病伴舒張性心力衰竭[J];中醫(yī)臨床研究;2011年18期
8 韓冰;周進(jìn)超;盧福建;;芪強心膠囊治療舒張性心力衰竭的臨床療效[J];臨床醫(yī)學(xué);2014年07期
9 徐立宏;;通心絡(luò)膠囊治療舒張性心力衰竭臨床觀察[J];遼寧中醫(yī)藥大學(xué)學(xué)報;2007年01期
10 楊萍;李華;章永南;涂秋英;李紅;吳艷;;參附注射液治療舒張性心力衰竭的臨床療效及機制研究[J];中藥藥理與臨床;2014年04期
相關(guān)重要報紙文章 前1條
1 宋維義;何為舒張性心力衰竭[N];家庭醫(yī)生報;2006年
相關(guān)碩士學(xué)位論文 前7條
1 邵楠;益氣養(yǎng)陰活血法治療舒張性心力衰竭療效的臨床觀察[D];遼寧中醫(yī)藥大學(xué);2014年
2 肖嬌;益氣養(yǎng)陰法對舒張性心力衰竭患者心室重構(gòu)的影響[D];廣州中醫(yī)藥大學(xué);2014年
3 黃孟龍;舒張性心力衰竭的證素研究[D];福建中醫(yī)藥大學(xué);2013年
4 劉寧;中藥益心顆粒對高血壓病伴舒張性心力衰竭的臨床研究[D];南京中醫(yī)藥大學(xué);2007年
5 李振軍;仙人活心膠囊對舒張性心力衰竭患者血漿腦鈉素值的影響[D];陜西中醫(yī)學(xué)院;2006年
6 劉亮亮;心衰Ⅰ號治療舒張性心力衰竭的臨床研究[D];南京中醫(yī)藥大學(xué);2012年
7 王強;心衰Ⅰ號治療舒張性心力衰竭的臨床研究[D];南京中醫(yī)藥大學(xué);2013年
，本文編號：2137304
本文鏈接：http://sikaile.net/zhongyixuelunwen/2137304.html
最近更新
教材專著
